OMedLive

CME Presentations

Carcinoid Syndrome


Presentations

  • CME
    1.0

    Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment

    Speakers:Matthew H. Kulke, MD, MMSc, Associate Professor of Medicine
    David C. Metz, MBBCh, Professor of Medicine

    Duration: 60 minutes

    Presented on: June 14, 2017


Speakers

  • Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Associate Professor of Medicine

    Matthew Kulke, MD, MMSc, is director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Kulke has played a leading role in the molecular characterization of neuroendocrine tumors and in developing new treatments for this indication, including sunitinib, temozolomide everolimus, and telotristat ethyl. He serves on the gastrointestinal cancer committee for the Cancer and Leukemia Group B, the advisory board for the European Neuroendocrine Tumor Society, and chairs the neuroendocrine tumor guidelines panel for the National Comprehensive Cancer Network. He received his MD from the University of California, San Francisco School of Medicine and his MMSc from Harvard Medical School.
  • David C. Metz, MBBCh

    David C. Metz, MBBCh

    David C. Metz, MBBCh

    Professor of Medicine

    David C. Metz, MBBCh, is a professor of medicine and associate chief for clinical affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is director of the Acid-Peptic Disease Program and co-director of the GI Physiology Laboratory, the Swallowing Disorders Program and the Neuroendocrine Tumor Program. His clinical research investigates Zollinger-Ellison syndrome, H. pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He has expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. Dr Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa.

CME Information

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment

 

Provided by the University of Nebraska Medical Center, Center for Continuing Education

ACKNOWLEDGEMENT This activity is supported by an educational grant from Lexicon Pharmaceuticals, Inc.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and PlatformQ Health Education. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Activity The University of Nebraska Medical Center, Center for Continuing Education designates the live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hour of credit for completing this program.

DATE OF RELEASE/EXPIRATION Live Activity Wednesday, June 14, 2017 from 12:00 PM EST – 1:00 PM EST Enduring Material The enduring material will be available from June 14, 2017 – June 14, 2018.

ACTIVITY DESCRIPTION Approximately 12,000 new cases of carcinoid tumors, a type of neuroendocrine tumor, are diagnosed annually in the U.S., of which about 10% manifest with carcinoid syndrome. Common symptoms of carcinoid syndrome are diarrhea and flushing, which pose diagnostic challenges for clinicians who may not know about the syndrome or do not consider it due to its rarity. The main goals of carcinoid tumor management are symptom control, biochemical control and quality-of-life improvement. Symptom control with somatostatin analogues (SSA) such as octreotide and lanreotide may be effective for some patients. For others unable to achieve adequate symptom relief with SSA, an increasing understanding of the pathophysiology of carcinoid syndrome and the effects of serotonin produced by neuroendocrine tumors has enabled the development of targeted treatment. Among these is telotristat etiprate, a serotonin synthesis inhibitor shown to decrease tumoral serotonin production and reduce daily bowel movements. Clinicians must be aware of safety and efficacy data of all treatment options to control carcinoid syndrome symptoms and improve quality of life. This program intends to facilitate the ability to address practice challenges in diagnosis and treatment of carcinoid syndrome, and provide clinicians with an opportunity for open dialogue and discussion with experts on making evidence-based informed decisions and optimize patient outcomes.

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Summarize the cause of carcinoid syndrome
Perform an appropriate workup and differential diagnosis from presenting symptoms
Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
Evaluate safety and efficacy of current and emerging treatment approaches for carcinoid syndrome
 

INTENDED AUDIENCE This activity is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome. Considering the symptoms and potential complications involved in carcinoid syndrome, clinicians in cardiology, dermatology, pulmonary medicine, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.omedlive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters Disclosures
Matthew Kulke, MD, MMSc

Consultant: Ipsen; Lexicon, Novartis

David C. Metz, MD

Consultant: Lexicon; Novartis; Takeda Grants/Research Support Recipient: AAA; Ipsen; Ironwood; Lexicon; Wren Labs

 

University of Nebraska Medical Center, Center for Continuing Education  
Lois Colburn, Executive Director Has nothing to disclose.
Brenda C. Ram, CMP, CHCP, Coordinator Has nothing to disclose.
PlatformQ Health Education, LLC Disclosures
Anne Roc, PhD, Medical Director Has nothing to disclose.
Karen Greb-Murphy, Program Manager Has nothing to disclose.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): The University of Nebraska Medical Center, Center for Continuing Education requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material. The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Nebraska Medical Center, Center for Continuing Education, OMedLive, PlatformQ Health or the program grantors. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

CONTACT INFORMATION Accreditation Support: Please contact the University of Nebraska Medical Center, Center for Continuing Education at conted@unmc.edu or call 402-559-4152. Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.